Stahl Neil's Form 4 filing
Regeneron Pharmaceuticals, Inc. (REGN) · filed Aug 23, 2023
- Accession no.
- 0001968202-23-000023
- Filed
- Aug 23, 2023
- Trade date
- Aug 21-22, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $9.81M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Stahl NeilCIK 0001226689 | Officer (EVP Research and Development) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 21, 2023 | Common Stock | MOption exerciseAcquired | +50,000 | $399.66 | +$19,983,000 | 103,100 | Direct | |
| Aug 21, 2023 | Common Stock | FTax withholdingDisposed | −38,335 | $833.39 | −$31,948,005.65 | 64,765 | Direct | |
| Aug 22, 2023 | Common Stock | SSaleDisposed | −6,309 | $840.53F1 | −$5,302,903.77 | 58,456 | Direct | |
| Aug 22, 2023 | Common Stock | SSaleDisposed | −4,574 | $841.41F2 | −$3,848,609.34 | 53,882 | Direct | |
| Aug 22, 2023 | Common Stock | SSaleDisposed | −782 | $842.16F3 | −$658,569.12 | 53,100 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 21, 2023 | Common Stock | MOption exerciseDisposed | −50,000 | $0.00 | $0 | 30,750 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents volume-weighted average price of sales of 6,309 shares of Company stock on August 22, 2023 at prices ranging from $840.00 to $840.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 22, 2023 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F2
Represents volume-weighted average price of sales of 4,574 shares of Company stock on August 22, 2023 at prices ranging from $841.01 to $841.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 22, 2023 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
Represents volume-weighted average price of sales of 782 shares of Company stock on August 22, 2023 at prices ranging from $842.01 to $842.23. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 22, 2023 at each separate price.
Referenced by the price of 1 transaction in Table I.